首页> 美国卫生研究院文献>Molecular and Clinical Oncology >Small-cell lung cancer with recurrent syncope as the initial symptom: A case report and literature review
【2h】

Small-cell lung cancer with recurrent syncope as the initial symptom: A case report and literature review

机译:复发性晕厥为首发症状的小细胞肺癌:一例病例报告并文献复习

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Small-cell lung cancer (SCLC) presenting with syncope as the initial symptom is rare in adults. This onset of tumour-induced syncope cannot be screened or differentiated by coronary angiography, magnetic resonance angiography of the neck or 24-hour dynamic electrocardiogram. We herein describe the case of a 61-year-old man who presented with recurrent syncope that resolved after the first course of chemotherapy (carboplatin plus etoposide) for SCLC. A mass measuring 57×53 mm was identified in the left hilum, and a diagnosis of limited-disease SCLC (T4N2M0, IIIB) was made. Considering the rapid and complete remission after the treatment of the primary lesion, we hypothesised that the syncope was neurogenic and associated with cancer. Thus, 8 similar cases retrieved from PubMed were reviewed and, for the first time, the mechanism underlying the syncope was identified, which may involve tumour location, neurobiology and other inducing factors. Thus, for the treatment of such SCLC patients, standard chemotherapy is crucial for preventing syncopal attacks.
机译:以晕厥为初始症状的小细胞肺癌(SCLC)在成年人中很少见。肿瘤引起的晕厥的发作无法通过冠状动脉造影,颈部磁共振血管造影或24小时动态心电图进行筛查或区分。我们在此描述了一名61岁男性患者的复发性晕厥病例,该患者在SCLC的第一个化疗疗程(卡铂加依托泊苷)后消退。在左肺门中鉴定出质量为57×53 mm的肿块,并诊断为疾病受限的SCLC(T4N2M0,IIIB)。考虑到原发灶治疗后迅速而完全缓解,我们假设晕厥是神经性的,并与癌症有关。因此,回顾了从PubMed检索到的8个类似病例,并首次确定了晕厥的潜在机制,这可能涉及肿瘤的位置,神经生物学和其他诱导因素。因此,对于这类SCLC患者的治疗,标准化学疗法对于预防晕厥发作至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号